Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions David Driscoll
ConjuChem IncCJB.TODON'T BUYJul 15, 2004
A negative report on patient's reactions created a drop in the stock. Drugs in phase one or phase two trials can be very volatile. Prefers larger companies.
$4.80
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
DON'T BUY
Thinks it will bounce around a little bit. Not his favourite name. Continue to spend a lot of money and ultimately will have to come back to the market, perhaps some time next year. With the state of biotechs, both large and small, it is not a sector he would want to be in right now. Doesn't like the management.
biotechnologypharmaceutical
WEAK BUY
Feels there is a potential drug here. Probably is near its bottom. A fair risk/reward. They are trying a new formulation re: nausea of the drugs they tested in phase 2 trials. Also waiting for a combination trial.
Martin Hubbes, CFAOwned
biotechnologypharmaceutical
TOP PICK
Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap.
Ed HoOwned
biotechnologypharmaceutical
DON'T BUY
Not sure you should buy it at this time. You want to hold it when there is a possibility of approval being given for their product.
Michael SmedleyOwned
biotechnologypharmaceutical
BUY
An announcement is coming out next week and he thinks the news will be good, but would like it to be great. Speculative. Good management and balance sheet.
Peter HodsonOwned
biotechnologypharmaceutical
BUY
Stock has come off since they announced the successful trials on their diabetes applications. There is some risk, but has potential.
Michael SmedleyOwned
biotechnologypharmaceutical
